Evofem Biosciences

197 articles about Evofem Biosciences

• Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter

  9/23/2022

  Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).  

• Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide

  9/16/2022

  Evofem Biosciences, Inc. announced another new insurance win that gives millions of additional women access to Phexxi® for the prevention of pregnancy.

• Evofem Announces Successful Debt Restructuring

  9/16/2022

  Evofem Biosciences, Inc. announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.

• Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance

  8/4/2022

  Evofem Biosciences, Inc., reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.

• Evofem Biosciences Strengthens Board of Directors

  8/3/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip , a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors.

• Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women

  8/1/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women.

• Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals

  7/29/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections for birth control coverage  under the Affordable Care Act (ACA).

• Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022

  7/28/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows.

• Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition

  7/26/2022

  Evofem Biosciences, Inc., announced a series of industry awards and recognition for the company's direct-to-consumer advertising campaign, House Rules.

• Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling

  7/25/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United States.

• Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act

  7/22/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.

• Evofem Partners with a360 Media to Support Phexxi® Prescription Growth

  7/21/2022

  Evofem Biosciences, Inc., announced an agreement between Evofem and a360 Media under which Phexxi® branded content will appear in some of the most widely read entertainment and lifestyle magazines and websites in the U.S.

• Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health

  7/12/2022

  Evofem Biosciences, Inc., announced that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products, a peer-reviewed article defining and reconfirming the mechanism of action of Phexxi®.

• Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO

  6/30/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides."

• Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®

  6/28/2022

  Evofem Biosciences, Inc., announced it has reached an agreement with one of the nation's largest pharmacy benefit managers to ensure most women covered by this plan can fill their Phexxi® prescriptions for pregnancy prevention, without restrictions such as prior authorization or step therapy.

• Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data

  6/16/2022

  Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy.

• US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years

  6/2/2022

  Evofem Biosciences, Inc. announced that the U.S. Food and Drug Administration has formally extended the shelf life of Phexxi® from three to four years.

• Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering

  5/20/2022

  Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock.

• Evofem Biosciences Announces Proposed Public Offering - May 19, 2022

  5/19/2022

  Evofem Biosciences, Inc. announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

• Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®

  5/10/2022

  Evofem Biosciences, Inc., announced it has selected Bora Pharmaceuticals Services Inc. Canada as Evofem's new contract manufacturing organization.